Half-year report · Q2
7745.TEDINET S100URZ6
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥62.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥29.3bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥8.2bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.3bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥2.2bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥66.7bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥72.0bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥71.2bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥28.6bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥34.2bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥38.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥37.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥34.5bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.5bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥14.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.0bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥15.6bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥14.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥3.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥7.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥613m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥64.38 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥192.91 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥78.3 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥64.32 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥192.73 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥78.23 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 57.0% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.3% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.3% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥14.4bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥1.2bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥156m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥65m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥144m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥307m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥229m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥199m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥346m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥346m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥4.4bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥221m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥9.4bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥301m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥8.7bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥16.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥13.3bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥543m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥22.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.7bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥10.9bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.4bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥12.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥12.8bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.6bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥182m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥26m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥4.6bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥276m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥184m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥178m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.1bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥246m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥287m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥287m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | −¥34m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥284m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥9.2bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥7.8bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥185m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥5.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥15.4bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥12.5bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.9bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥361m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥21.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥11.2bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥9.9bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥5.7bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥2.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 613
| Item | Context | Value | Unit |
|---|---|---|---|
| Income before income taxes | Prior1YTDDuration | 3404000000 | JPY |
| Income before income taxes | CurrentYTDDuration | 3179000000 | JPY |
| Depreciation and amortization ope cf | Prior1YTDDuration | 837000000 | JPY |
| Depreciation and amortization ope cf | CurrentYTDDuration | 876000000 | JPY |
| Amortization of goodwill ope cf | Prior1YTDDuration | 23000000 | JPY |
| Amortization of goodwill ope cf | CurrentYTDDuration | 8000000 | JPY |
| Depreciation of trademark | Prior1YTDDuration | 0 | JPY |
| Depreciation of trademark | CurrentYTDDuration | 0 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | Prior1YTDDuration | 51000000 | JPY |
| Increase decrease in allowance for doubtful accounts ope cf | CurrentYTDDuration | -28000000 | JPY |
| Interest and dividends income ope cf | Prior1YTDDuration | -117000000 | JPY |
| Interest and dividends income ope cf | CurrentYTDDuration | -226000000 | JPY |
| Interest expenses ope cf | Prior1YTDDuration | 202000000 | JPY |
| Interest expenses ope cf | CurrentYTDDuration | 174000000 | JPY |
| Commission for syndicate loan ope cf | Prior1YTDDuration | 34000000 | JPY |
| Commission for syndicate loan ope cf | CurrentYTDDuration | － | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | Prior1YTDDuration | 199000000 | JPY |
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYTDDuration | 4052000000 | JPY |
| Decrease increase in inventories ope cf | Prior1YTDDuration | -319000000 | JPY |
| Decrease increase in inventories ope cf | CurrentYTDDuration | -1195000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | Prior1YTDDuration | -139000000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYTDDuration | -642000000 | JPY |
| Increase decrease in provision for bonuses ope cf | Prior1YTDDuration | 25000000 | JPY |
| Increase decrease in provision for bonuses ope cf | CurrentYTDDuration | 66000000 | JPY |
| Increase decrease in provision for product warranties ope cf | Prior1YTDDuration | 104000000 | JPY |
| Increase decrease in provision for product warranties ope cf | CurrentYTDDuration | -101000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | Prior1YTDDuration | 122000000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | CurrentYTDDuration | -122000000 | JPY |
| Increase decrease in net defined benefit asset ope cf | Prior1YTDDuration | － | JPY |
| Increase decrease in net defined benefit asset ope cf | CurrentYTDDuration | 26000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | Prior1YTDDuration | -79000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYTDDuration | -1000000 | JPY |
| Other net ope cf | Prior1YTDDuration | 497000000 | JPY |
| Other net ope cf | CurrentYTDDuration | -1410000000 | JPY |
| Subtotal ope cf | Prior1YTDDuration | 4847000000 | JPY |
| Subtotal ope cf | CurrentYTDDuration | 4654000000 | JPY |
| Interest and dividends income received ope cf inv cf | Prior1YTDDuration | 114000000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYTDDuration | 225000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1YTDDuration | -199000000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYTDDuration | -176000000 | JPY |
| Income taxes paid ope cf | Prior1YTDDuration | -1581000000 | JPY |
| Income taxes paid ope cf | CurrentYTDDuration | -1705000000 | JPY |
| Net cash provided by used in operating activities | Prior1YTDDuration | 3180000000 | JPY |
| Net cash provided by used in operating activities | CurrentYTDDuration | 2997000000 | JPY |
| Payments into time deposits inv cf | Prior1YTDDuration | -276000000 | JPY |
| Payments into time deposits inv cf | CurrentYTDDuration | -316000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | Prior1YTDDuration | 262000000 | JPY |
| Proceeds from withdrawal of time deposits inv cf | CurrentYTDDuration | 321000000 | JPY |
| Purchase of property plant and equipment inv cf | Prior1YTDDuration | -410000000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYTDDuration | -438000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |